Heart failure drug before hospital stay may improve outcomes, study suggests

NCT ID NCT07347925

Recruiting now Disease control Sponsor: Future University in Egypt Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 140 heart failure patients to see if taking a medicine called ARNI before coming to the hospital leads to better short-term health. Researchers will compare those who were already on ARNI with those who were not, tracking heart and kidney events during the hospital stay and shortly after discharge. The goal is to understand if pre-hospital use of this drug is linked to better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: angiotensin receptor-neprilysin inhibitor (ARNI)
What this could lead to: If successful, this study could show that starting ARNI before a hospital visit improves short-term heart and kidney outcomes in heart failure patients.
What could go wrong: This is an observational study, not a randomized trial, so results may be influenced by other factors. It is also relatively small and only looks at short-term effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic renal failure syndrome heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE

Contacts and locations

Locations

Mansoura university Hospital
RECRUITING

Al Mansurah, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.